Ipsen: European Commission Approves Cabometyx as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1 This milestone

Related Keywords

Hebron ,Israel General ,Israel ,Serbia ,Saclay ,France General ,France ,Australia ,Taiwan ,United States ,Shanghai ,China ,United Kingdom ,Hong Kong ,Paris ,Brazil ,Russia ,Ukraine ,Mexico ,Iceland ,New Zealand ,Egypt ,Ecuador ,Cambridge ,Cambridgeshire ,Panama ,South Korea ,Switzerland ,Macau ,Norway ,Malaysia ,Japan ,Lebanon ,Colombia ,Canada ,Guatemala ,Jordan ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Thailand ,Singapore ,Dominican Republic ,Saudi Arabia ,Chile ,Peru ,Turkey ,Great Britain ,Russian Federation ,American ,Jaume Capdevila ,Gemma Roper ,Ipsen Euronext ,Hebron University Hospital ,European Commission ,Takeda Pharmaceutical Company ,Global Franchise Communications ,European Thyroid Association Guidelines For The Treatment ,Global Head Of Franchise Communications ,Hebron Institute Of Oncology ,European Union ,Medical Oncologist ,Hebron Institute ,United Arabic Emirates ,Product Characteristics ,Takeda Pharmaceutical Company Limited ,Rare Disease ,Sponsored Leveli American Depositary Receipt ,Forward Looking Statements ,French Autorit ,Des March ,Registration Document ,Cancer Journal For ,Adv Med ,Thyroid Association Guidelines ,Advanced Radioiodine Refractory Thyroid ,Eur Thyroid ,Investor Relations ,Relations Manager ,Franchise Communications ,Lipsen ,European ,Commission ,Pproves ,Cabometyx ,Second ,Line ,Treatment ,People ,Diving ,Ith ,Radioactive ,Iodine ,Refractory ,Differentiated ,Thyroid ,Dancer ,